---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040232"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:10:50.704038+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics reports FY2024 revenue $105.8M, issues FY2025 guidance $118-128M; Phase 3 data due Q2 2025

## Summary
- FY2024 revenue $105.8M (down 6.8% YoY); net income $17.9M vs loss $85.5M in 2023 on absence of IPR&D charge.
- Non-GAAP adjusted net income $16.9M (down from $25.4M); cash $51.2M at year-end.
- FY2025 revenue guidance $118-128M (11-21% growth) driven by planned launches of nintedanib and avatrombopag in China.
- Pivotal Phase 3 trial of F351 in CHB-associated liver fibrosis topline data expected Q2 2025; U.S. Phase 2 in MASH planned.
- Appointed Ping Zhang as lead independent director; Songjiang Ma appointed Chairman of Gyre Pharmaceuticals board.

## SEC filing metadata
- accession: 0000950170-25-040232
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/0000950170-25-040232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000095017025040232/gyre-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040232
- JSON: https://secwatch.observer/filing/0000950170-25-040232.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.